cnl_21

Epac - Associazione Onlus

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Malattie autoimmuni

Fai una donazione

Sostieni EpaC Onlus

Newsletter EpaC

Aggiornati via email. Iscriviti

Notiziario Epac

Periodico cartaceo. Iscriviti

Sangue Infetto

Visita il sito - legge 210/92

News nuovi farmaci in Inglese

Phase 3 Randomized Controlled Trial of All-Oral Treatment With Sofosbuvir + Ribavirin for 12 Weeks Compared to 24 Weeks of PEG + Ribavirin in Treatment-Naïve GT 2/3 HCV-Infected Patients (FISSION)

03/05/2013

SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY

03/05/2013

Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUesT-1, a Phase III trial

03/05/2013

Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC)

03/05/2013

Boehringer Ingelheim announces results from one of its HCV Phase III trials: Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C

03/05/2013

Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients

03/05/2013

Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™

03/05/2013

DATA FROM PHASE 3 STUDIES OF GILEAD’S SOFOSBUVIR FOR HEPATITIS C TO BE PRESENTED AT 48TH ANNUAL EASL MEETING; FINDINGS PUBLISHED ONLINE TODAY IN THE NEW ENGLAND JOURNAL OF MEDICINE

03/05/2013

New Data from AbbVie’s Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1

03/05/2013

High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection

03/05/2013

ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection

03/05/2013

GILEAD SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR SOFOSBUVIR FOR THE TREATMENT OF HEPATITIS C

09/04/2013

Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C

02/04/2013

Micromanaging Hepatitis C Virus

28/03/2013

SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders

11/03/2013

12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NAIVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS

07/03/2013

ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1

07/03/2013

High Efficacy of Sofosbuvir in Combination with Weight Based Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype-1 Patients

07/03/2013

First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients - press release

07/03/2013

GILEAD’S SOFOSBUVIR FOR HEPATITIS C MEETS PRIMARY ENDPOINT IN FOURTH PIVOTAL PHASE 3 STUDY

19/02/2013

Pagina: 1 2 3 4 5

© Copyright 2015 - Associazione EpaC Onlus - C.F. 97375600158

Via Col. Tommaso Masala, 42
C/O Parco Altamira - 00148 Roma

Tel. 06.60200566 | Fax 06.60209056
Orari ufficio: 9.00-12.00 e 14.00-17.00

Via Luigi Cadorna, 17/A
20871 Vimercate Monza e Brianza

Tel. 0396083527 | Fax 039 6611523
Orari ufficio: 9.00-12.00 e 14.00-17.00

ACE - Alleanza Contro Epatiti World Hepatitis Alliance ELPA - European Liver Patients Associations